Caribou Biosciences, Inc. (CRBU) Earnings Call Transcripts

Caribou Biosciences, Inc.'s Latest Earnings Call - June 4, 2026

In the second quarter of fiscal year 2026, Caribou Biosciences, Inc. (CRBU:US) showcased significant advancements in its clinical programs, particularly vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma. Management highlighted that vispa-cel is now 'pivotal-ready' and has demonstrated outcomes comparable to autologous CAR-T therapies, which positions it favorably in the market. The company maintained its guidance for upcoming data releases, including pivotal study results and dose expansion data, which could drive stock performance in the near term.

Reported metrics

Guidance from management

Caribou maintained its timeline for pivotal study execution, expecting data from the ANTLER-3 study in approximately two years. Initial dose expansion data for CB-011 is anticipated by the end of this year.

What management said

Maybe I'll just quickly say it's a 250-patient study, and the primary endpoint will be progression-free survival. And just to explain that in a bit more detail, it's not a landmark PFS. There's not a magic date in the calendar that we've circled. It's really event-driven, which is why we have such high confidence in the very high likelihood of technical success for vispa-cel over these other agents that, again, have ...

Yes. I'd say success equals more of the same, right? What we've shown historically is data that is really indistinguishable from the autologous CAR-T cell therapies both in terms of overall response rate and complete response rate as well as how durable these responses can be. So more of the same would be, I think, very encouraging and would certainly be success in our minds. And keep in mind, we're running a study w...

What analysts pressed on

Analysts expressed concerns over the competitive landscape for CAR-T therapies, particularly regarding the potential impact of bispecific antibodies on market share. There was also inquiry about the company's financing strategy to support pivotal trials amid cash constraints.

Main topics on the call

• Pivotal Study Readiness for vispa-cel — Caribou announced that vispa-cel is 'pivotal-ready' following a successful Phase I study. The company is preparing for a randomized controlled trial targeting a significant patient population that currently lacks access ...
• FDA Alignment on ANTLER-3 Study — Management confirmed alignment with the FDA on the pivotal ANTLER-3 study design, which includes enrolling patients who are medically ineligible for auto CAR-T. This endorsement is expected to enhance enrollment and exec...
• Response Rates for CB-011 — The company reported that CB-011 is showing response rates 'far exceeding our benchmark' for bispecific antibodies, approaching auto CAR-T-like response rates. This positions CB-011 favorably in a competitive market.
• Market Positioning and Access Challenges — Management emphasized that 75% of second-line large B-cell lymphoma patients do not receive auto CAR-T due to access challenges. This presents a significant market opportunity for vispa-cel, which can be delivered 'off-t...

Read the full Caribou Biosciences, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Caribou Biosciences, Inc. earnings call transcripts on record, spanning January 16, 2025 to June 4, 2026. Based on this history, Caribou Biosciences, Inc. reports quarterly. The most recent call on file is dated June 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CRBU

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

6

First call

January 16, 2025

Most recent

June 4, 2026

Reporting cadence

quarterly